Eric Lefevbre

Eric Lefevbre

Company: Pliant Therapeutics

Job title: Chief Medical Officer


: Evaluating the Safety and Tolerability of PLN-74809, a Dual-Selective Inhibitor of Integrins αvβ6 and αvβ1 9:00 am

No treatment-related effects in chronic GLP toxicology studies; NOAEL set at the highest dose tested PLN-74809 has been administered to over 450 study participants to date and shown to be well tolerated Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to evaluate dosing at…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.